Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma

Hyunsoo Cho, Se Hoon Kim, Soo Jeong Kim, Jong Hee Chang, Woo Ick Yang, Chang Ok Suh, Yu Ri Kim, Ji Eun Jang, June Won Cheong, Yoo Hong Min, Jin Seok Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Programmed cell death 1 (PD-1) and its ligands PD-L1/PD-L2 have been shown to mediate immune evasion in various cancers, but their prognostic implications in patients with primary central nervous system lymphoma (PCNSL) are poorly understood. Therefore, we analyzed 76 PCNSL patients at initial diagnosis who were treated homogenously with high-dose methotrexate-based chemotherapy, and evaluated the prognostic roles of high immunohistochemical PD-1, PD-L1, and PD-L2 expression. The cut-off values for high PD-1 (≥ 70 cells/high power field [HPF]), PD-L1 (≥ 100 cells/HPF), and PD-L2 (≥ 100 cells/HPF) were determined by the area under the receiver operating characteristic curve. Expression of PD-1, PD-L1, and PD-L2 was high in 7.9%, 13.2%, and 42.1% patients, respectively. High PD-1, (P = 0.007) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring (P = 0.019) were independently associated with inferior overall survival on multivariate analysis. High PD-1 also remained an independent prognostic factor for inferior progression-free survival (P = 0.028), as did MSKCC prognostic scoring (P = 0.041) on multivariate analysis. However, there were no differences in survival according to the expression levels of PD-L1/PD-L2 in PCNSL tumor microenvironment. Our results suggest that PD-1 may be considered a biomarker and potential therapeutic target in PCNSL.

Original languageEnglish
Pages (from-to)87317-87328
Number of pages12
JournalOncotarget
Volume8
Issue number50
DOIs
Publication statusPublished - 2017 Jan 1

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this